GP40221 + ozempic

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pharmacokinetics

Conditions

Pharmacokinetics, Safety Issues, Bioequivalence

Trial Timeline

Jun 30, 2023 → May 5, 2024

About GP40221 + ozempic

GP40221 + ozempic is a phase 1 stage product being developed by GEROPHARM for Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT06497049. Target conditions include Pharmacokinetics, Safety Issues, Bioequivalence.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06497049Phase 1Completed

Competing Products

20 competing products in Pharmacokinetics

See all competitors